Background: Contrary to deeply located brain arteriovenous malformations (AVMs), superficially located AVMs are more likely to have transdural arterial communications (TACs). However, the clinical and radiologic characteristics of patients presenting with AVMs and TACs are poorly understood. The purpose of this study is to determine whether clinicoradiological features of cerebral AVMs differ according to TAC. Methods: Between 2002 and 2012, 438 consecutive patients with a brain AVM were treated in our hospital. Among them were 124 patients with superficially located brain AVMs who met the inclusion and exclusion criteria of our study. We retrospectively reviewed the clinicoradiological features of their TACs to explore the variation in characteristics. Results: Thirty-two of the 124 patients with a superficially located AVM (25.8%) had TAC. Radiologic findings of brain AVM images with TAC showed that TAC occurred significantly more frequently among larger AVMs (with vs. without TAC, 11.2 vs. 4.0 ml) and among diffuse AVMs (56.3 vs. 28.3%, p = 0.004). Clinical findings indicate that TAC was associated with chronic headache (43.8 vs. 12.0%, p < 0.001) and older age (43.1 vs. 36.6 years, p = 0.037). Conclusions: Brain AVM with TAC seems to be accompanied by distinctive clinical features, such as chronic headache and older age. Larger size and diffuseness of the AVM were also associated with TAC. Findings from this study and the prognostic significance of TAC should be further explored in a large prospective study.

Keywords:
Transdural arterial communication, Arteriovenous malformation, Superficially located AVM, Clinical feature
1.
Soderman M, Rodesch G, Lasjaunias P: Transdural blood supply to cerebral arteriovenous malformations adjacent to the dura mater. AJNR Am J Neuroradiol 2002;23:1295-1300.
2.
Miyachi S, Negoro M, Handa T, Sugita K: Contribution of meningeal arteries to cerebral arteriovenous malformations. Neuroradiology 1993;35:205-209.
3.
Newton TH, Cronqvist S: Involvement of dural arteries in intracranial arteriovenous malformations. Radiology 1969;93:1071-1078.
4.
Willinsky R, Lasjaunias P, Terbrugge K, Pruvost P: Brain arteriovenous malformations: analysis of the angio-architecture in relationship to hemorrhage (based on 152 patients explored and/or treated at the hopital de bicetre between 1981 and 1986). J Neuroradiol 1988;15:225-237.
5.
Bendjilali N, Nelson J, Weinsheimer S, Sidney S, Zaroff JG, Hetts SW, Segal M, Pawlikowska L, McCulloch CE, Young WL, Kim H: Common variants on 9p21.3 are associated with brain arteriovenous malformations with accompanying arterial aneurysms. J Neurol Neurosurg Psychiatry 2014;85:1280-1283.
6.
Sturiale CL, Gatto I, Puca A, D'Arrigo S, Giarretta I, Albanese A, Di Rocco C, Maira G, Pola R: Association between the rs1333040 polymorphism on the chromosomal 9p21 locus and sporadic brain arteriovenous malformations. J Neurol Neurosurg Psychiatry 2013;84:1059-1062.
7.
Sturiale CL, Puca A, Sebastiani P, Gatto I, Albanese A, Di Rocco C, Maira G, Pola R: Single nucleotide polymorphisms associated with sporadic brain arteriovenous malformations: where do we stand? Brain 2013;136(pt 2):665-681.
8.
Kim H, Su H, Weinsheimer S, Pawlikowska L, Young WL: Brain arteriovenous malformation pathogenesis: a response-to-injury paradigm. Acta Neurochir Suppl 2011;111:83-92.
9.
Mathon B, Blauwblomme T, Bolle S, Dufour C, Nagarra O, Brunelle F, Puget S: De novo arteriovenous malformation after brain radiotherapy for medulloblastoma in a child. Neurology 2013;81:398-399.
10.
Miller BA, Bass DI, Chern JJ: Development of a de novo arteriovenous malformation after severe traumatic brain injury. J Neurosurg Pediatr 2014;14:418-420.
11.
Dehdashti AR, Thines L, Willinsky RA, terBrugge KG, Schwartz ML, Tymianski M, Wallace MC: Multidisciplinary care of occipital arteriovenous malformations: effect on nonhemorrhagic headache, vision, and outcome in a series of 135 patients. Clinical article. J Neurosurg 2010;113:742-748.
12.
Kupersmith MJ, Vargas ME, Yashar A, Madrid M, Nelson K, Seton A, Berenstein A: Occipital arteriovenous malformations: visual disturbances and presentation. Neurology 1996;46:953-957.
13.
Joint Writing Group of the Technology Assessment Committee American Society of Interventional and Therapeutic Neuroradiology; Joint Section on Cerebrovascular Neurosurgery a Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons; Section of Stroke and the Section of Interventional Neurology of the American Academy of Neurology, Atkinson RP, Awad IA, Batjer HH, Dowd CF, Furlan A, Giannotta SL, Gomez CR, Gress D, Hademenos G, Halbach V, Hemphill JC, Higashida RT, Hopkins LN, Horowitz MB, Johnston SC, Lawton MW, McDermott MW, Malek AM, Mohr JP, Qureshi AI, Riina H, Smith WS, Pile-Spellman J, Spetzler RF, Tomsick TA, Young WL: Reporting terminology for brain arteriovenous malformation clinical and radiographic features for use in clinical trials. Stroke 2001;32:1430-1442.
14.
Speizler RF, Martin NA: A proposed grading system for arteriovenous malformations. J Neurosurg 2008;108:186-193.
15.
Chin LS, Raffel C, Gonzalez-Gomez I, Giannotta SL, McComb JG: Diffuse arteriovenous malformations: a clinical, radiological, and pathological description. Neurosurgery 1992;31:863-868; discussion 868-869.
16.
Crawford PM, West CR, Chadwick DW, Shaw MD: Arteriovenous malformations of the brain: natural history in unoperated patients. J Neurol Neurosurg Psychiatry 1986;49:1-10.
17.
Waltimo O, Hokkanen E, Pirskanen R: Intracranial arteriovenous malformations and headache. Headache 1975;15:133-135.
18.
Bruyn GW: Intracranial arteriovenous malformation and migraine. Cephalalgia 1984;4:191-207.
19.
Kurita H, Ueki K, Shin M, Kawamoto S, Sasaki T, Tago M, Kirino T: Headaches in patients with radiosurgically treated occipital arteriovenous malformations. J Neurosurg 2000;93:224-228.
20.
Dahl RE, Kline DG: Intraparenchymal arteriovenous malformations with predominant external carotid artery contribution. J Neurosurg 1974;41:681-687.
21.
Hetts SW, Cooke DL, Nelson J, Gupta N, Fullerton H, Amans MR, Narvid JA, Moftakhar P, McSwain H, Dowd CF, Higashida RT, Halbach VV, Lawton MT, Kim H: Influence of patient age on angioarchitecture of brain arteriovenous malformations. AJNR Am J Neuroradiol 2014;35:1376-1380.
22.
Nakamura M, Imai H, Konno K, Kubota C, Seki K, Puentes S, Faried A, Yokoo H, Hata H, Yoshimoto Y, Saito N: Experimental investigation of encephalomyosynangiosis using gyrencephalic brain of the miniature pig: histopathological evaluation of dynamic reconstruction of vessels for functional anastomosis. Laboratory investigation. J Neurosurg Pediatr 2009;3:488-495.
23.
Guo Y, Saunders T, Su H, Kim H, Akkoc D, Saloner DA, Hetts SW, Hess C, Lawton MT, Bollen AW, Pourmohamad T, McCulloch CE, Tihan T, Young WL; University of California, San Francisco Brain Arteriovenous Malformation (UCSF bAVM) Study Project: Silent intralesional microhemorrhage as a risk factor for brain arteriovenous malformation rupture. Stroke 2012;43:1240-1246.
24.
Abla AA, Nelson J, Kim H, Hess CP, Tihan T, Lawton MT: Silent arteriovenous malformation hemorrhage and the recognition of ‘unruptured' arteriovenous malformation patients who benefit from surgical intervention. Neurosurgery 2015;76:592-600; discussion 600.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.